In turn, this pathway contains VEGF - molecular target of bevacizumab, one of most common CRC drugs (Table 3), which was not among the top activated nodes in favorable prognosis CRCs still was upregulated in them in three datasets (Fig. 3D-F). The gene discussed is VEGFA; the disease is colorectal carcinoma.